Carregant...
Safety of anti-tumor necrosis factor therapy during pregnancy in patients with inflammatory bowel disease
Treatment of inflammatory bowel disease has significantly improved since the introduction of biological agents, such as infliximab, adalimumab, certolizumab pegol, and golimumab. The Food and Drug Administration has classified these factors in category B, which means that they do not demonstrate a f...
Guardat en:
| Publicat a: | World J Gastroenterol |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Baishideng Publishing Group Inc
2015
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4679752/ https://ncbi.nlm.nih.gov/pubmed/26715803 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v21.i47.13205 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|